Tocilizumab in rheumatoid arthritis: A case study of safety evaluations of a large postmarketing data set from multiple data sources

Seminars in Arthritis and Rheumatism

Volumn 44, Issue 4, 2015, Pages 381-388

  Curtis, Jeffrey R ^a   Perez Gutthann, Susana ^b   Suissa, Samy ^c   Napalkov, Pavel ^d   Singh, Natasha ^d   Thompson, Liz ^e   Porter Brown, Benjamin ^d,e  

^a The University of Alabama at Birmingham   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d GENENTECH INC   (United States)

^e ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Postmarketing; Rheumatoid arthritis; Serious adverse events; Tocilizumab

Indexed keywords

TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG DATABASE; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG SAFETY; FEMALE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HEALTH INSURANCE; HUMAN; JAPAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SEX RATIO; AGED; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); DRUG-INDUCED LIVER INJURY; EUROPE; EVALUATION STUDY; GASTROINTESTINAL DISEASES; INCIDENCE; MIDDLE AGED; MORTALITY; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; UNITED STATES;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG-INDUCED LIVER INJURY; EUROPE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; SURVIVAL RATE; UNITED STATES;

EID: 84927621697     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2014.07.006     Document Type: Article

References (35)

1. Yazici Y., Shi N., John A. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. Bull NYU Hosp Jt Dis 2008, 66:77-85.
2. Vander Cruyssen B., Durez P., Westhovens R., De Keyser F. Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease. Arthritis Res Ther 2010, 12:R77.
3. Gomez-Reino J.J., Carmona L., for the BIOBADASER Group Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006, 8:R29.
4. Hyrich K.L., Lunt M., Watson K.D., Symmons D.P.M., Silman A.J., British Society for Rheumatology Biologics Register Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007, 56:13-20.
5. Buch M.H., Bingham S.J., Bryer D., Emery P. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Rheumatology (Oxford) 2007, 46:1153-1156.
6. Hashizume M., Mihara M. The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis 2011, 2011. (765624).
7. Assier E., Boissier M.C., Dayer J.M. Interleukin-6: from identification of the cytokine to development of targeted treatments. Joint Bone Spine 2010, 77:532-536.
8. Dayer J.M., Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford) 2010, 49:15-24.
9. Mihara M., Kasutani K., Okazaki M., Nakamura A., Kawai S., Sugimoto M., et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 2005, 5:1731-1740.
10. Nishimoto N., Terao K., Mima T., Nakahara H., Takagi N., Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008, 112:3959-3964.
11. Smolen J.S., Beaulieu A., Rubbert-Roth A., Ramos-Remus C., Rovensky J., Alecock E., et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008, 371:987-997.
12. Emery P., Keystone E., Tony H.P., Cantagrel A., van Vollenhoven R., Sanchez A., et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008, 67:1516-1523.
13. Genovese M.C., McKay J.D., Nasonov E.L., Mysler E.F., da Silva N.A., Alecock E., et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008, 58:2968-2980.
14. Kremer J.M., Blanco R., Brzosko S., Burgos-Vargas R., Halland A.M., Vernon E., et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011, 63(3):609-621.
15. Jones G., Sebba A., Gu J., Lowenstein M.B., Calvo A., Gomez-Reino J.J., et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010, 69:88-96.
16. Schiff M.H., Kremer J.M., Jahreis A., Vernon E., Isaacs J.D., van Vollenhoven R.F. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011, 13:1-13.
17. Simon L.S. Pharmacovigilance: towards a better understanding of the benefit to risk ratio. Ann Rheum Dis 2002, 61(Suppl. 2):ii88-ii89.
18. Buch M.H., Aletaha D., Emery P., Smolen J.S. Reporting of long-term extension studies: lack of consistency calls for consensus. Ann Rheum Dis 2011, 70:886-890.
19. US Food and Drug Administration (FDA). What is a serious adverse event? [accessed 30.04.2014]. http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm.
20. Solomon D.H., Kremer J., Curtis J.R., Hochberg M.C., Reed G., Tsao P., et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010, 69:1920-1925.
21. Suissa S., Ernst P., Hudson M., Bitton A., Kezouh A. Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. Am J Med 2004, 117:87-92.
22. Curtis J.R., Xie F., Chen L., Spettell C., McMahan R.M., Fernandes J., et al. The incidence of gastrointestinal perforations among rheumatoid arthritis patients. Arthritis Rheum 2011, 63:346-351.
23. Solomon D.H., Goodson N.J., Katz J.N., Weinblatt M.E., Avorn J., Setoguchi S., et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006, 65:1608-1612.
24. Curtis J.R., Jain A., Askling J., Bridges S.L., Carmona L., Dixon W., et al. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum 2010, 40:2-14.
25. Carmona L., Descalzo M.A., Perez-Pampin E., Ruiz-Montesinos D., Erra A., Cobo T., et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007, 66:880-885.
26. Leombruno J.P., Einarson T.R., Keystone E.C. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009, 68:1136-1145.
27. Curtis J.R., Lanas A., John A., Johnson D.A., Schulman K.L. Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis. Arthritis Care Res 2012, 64:1819-1828.
28. Curtis J.R., Lanas A., John A., Johnson D.A., Schulman K.L. Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis. Ann Rheum Dis 2011, 70:121.
29. Dixon W.G., Watson K.D., Lunt M., Hyrich K.L., Silman A.J., Symmons D.P. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007, 56:2905-2912.
30. Dixon W.G., Watson K.D., Lunt M., Hyrich K.L. Rates of myocardial infarction (MI) and cerebrovascular accident (CVA) are reduced in patients with rheumatoid arthritis (RA) treated with anti-TNF therapy compared to those treated with traditional DMARDs: results from the BSR Biologics Register. Rheumatology 2006, 45:i2.
31. Chan K.A., Hernandez-Diaz S. Pharmacoepidemiology and rheumatic disorders. Rheum Dis Clin North Am 2004, 30:835-850. [vii].
32. Hall G.C., Sauer B., Bourke A., Brown J.S., Reynolds M.W., Casale R.L. Guidelines for good database selection and use in pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2012, 21:1-10.
33. Nelson J.C., Cook A.J., Yu O., Dominguez C., Zhao S., Greene S.K., et al. Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data. Pharmacoepidemiol Drug Saf 2012, 21(Suppl.1):62-71.
34. Fletcher A.P. Spontaneous adverse drug reaction reporting vs event monitoring: a comparison. J R Soc Med 1991, 84:341-344.
35. Koike T., Harigai M., Inokuma S., Ishiguro N., Ryu J., Takeuchi T., et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis 2011, 70:2148-2151.